CN101104864A - 埃博霉素b的制备方法和用途 - Google Patents
埃博霉素b的制备方法和用途 Download PDFInfo
- Publication number
- CN101104864A CN101104864A CNA2006100910356A CN200610091035A CN101104864A CN 101104864 A CN101104864 A CN 101104864A CN A2006100910356 A CNA2006100910356 A CN A2006100910356A CN 200610091035 A CN200610091035 A CN 200610091035A CN 101104864 A CN101104864 A CN 101104864A
- Authority
- CN
- China
- Prior art keywords
- epothilone
- sorbent material
- fermentation
- lower alcohol
- imatinib mesylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 title claims abstract description 48
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 title claims abstract description 47
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims abstract description 19
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 18
- 238000000855 fermentation Methods 0.000 claims abstract description 12
- 230000004151 fermentation Effects 0.000 claims abstract description 12
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 3
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 23
- 229960003685 imatinib mesylate Drugs 0.000 claims description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000003463 adsorbent Substances 0.000 claims description 10
- 239000002594 sorbent Substances 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 244000068988 Glycine max Species 0.000 claims description 8
- 235000010469 Glycine max Nutrition 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 8
- 239000000287 crude extract Substances 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 229940041514 candida albicans extract Drugs 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000012138 yeast extract Substances 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000004744 fabric Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 5
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 4
- 150000001348 alkyl chlorides Chemical class 0.000 claims description 4
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 230000008595 infiltration Effects 0.000 claims description 4
- 238000001764 infiltration Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- -1 polyoxyethylene Polymers 0.000 claims description 4
- 238000002390 rotary evaporation Methods 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 238000004811 liquid chromatography Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000004262 preparative liquid chromatography Methods 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 238000000926 separation method Methods 0.000 abstract description 6
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract description 2
- 229940080856 gleevec Drugs 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 229930012538 Paclitaxel Natural products 0.000 description 9
- 229960001592 paclitaxel Drugs 0.000 description 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000012533 medium component Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000862997 Sorangium cellulosum Species 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- LMSDCGXQALIMLM-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;iron Chemical compound [Fe].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O LMSDCGXQALIMLM-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
编号 | δH(mult.J in Hz) | δc(mult.) | ||
文献值(CDCl3) | 样品值(CD3OD) | 文献值(CDCl3) | 样品值(CDCl3) | |
12a2b33-0H45677-OH89a9b10a10b11a11b121314a14b15161718192021222324252627 | 2.54(dd,J=14.1,9.6)2.35(dd,J=14.1,3.0)4.21(m)4.19(bs)3.29(dq)3.76(ddd)2.64(bd)1.73(m)1.42(m)1.42(m)1.49(m)1.42(m)1.70(m)1.42(m)2.80(dd,J=7.7,4.6)2.10(ddd)1.91(ddd)5.41(dd,J=7.8,3.0)6.58(bs)6.96(s)2.68(s)1.07(s)1.36(s)1.16(d,J=6.9)0.99(d,J=7.0)1.27(s)2.08(d,J=1.3) | 2.49(J=15,10.2)2.43(J=15,3.6)4.22--3.293.65--1.691.551.551.571.551.691.552.90(J=9,3.6)2.131.955.41(J=8.4,1.8)6.597.222.681.171.311.17(J=6.6)1.01(J=7.2)1.272.07(J=1.8) | 170.6(s)39.3(t)72.9(d)53.2(s)220.7(s)42.9(d)74.1(d)36.5(d)30.8(t)22.4(t)32.4(t)61.7(d)61.4(s)32.1(t)77.3(d)137.6(s)119.7(d)151.9(s)116.1(d)165.2(s)19.2(q)19.7(q)21.5(q)13.6(q)17.1(q)22.8(q)15.9(q) | 170.539.272.953.1220.642.974.136.430.822.832.161.361.732.477.0137.5119.7151.8116.1165.119.119.721.413.717.122.415.8 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100910356A CN101104864B (zh) | 2006-07-12 | 2006-07-12 | 埃博霉素b的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100910356A CN101104864B (zh) | 2006-07-12 | 2006-07-12 | 埃博霉素b的制备方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102593725A Division CN101732310B (zh) | 2006-07-12 | 2006-07-12 | 埃博霉素b的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101104864A true CN101104864A (zh) | 2008-01-16 |
CN101104864B CN101104864B (zh) | 2011-05-11 |
Family
ID=38998943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100910356A Active CN101104864B (zh) | 2006-07-12 | 2006-07-12 | 埃博霉素b的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101104864B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009100571A1 (zh) * | 2008-02-01 | 2009-08-20 | Zhejiang Hisun Pharmaceutical Co., Ltd. | 一种分离和提纯埃博霉素的方法 |
CN102276597A (zh) * | 2010-01-12 | 2011-12-14 | 山东大学 | 14元大环内酯类埃博霉素化合物及其应用 |
CN102373252A (zh) * | 2011-11-04 | 2012-03-14 | 陕西科技大学 | 一种埃博霉素b的发酵生产工艺 |
CN102373251A (zh) * | 2011-11-04 | 2012-03-14 | 陕西科技大学 | 一种添加分子印迹聚合物的埃博霉素d发酵生产方法 |
CN103243134A (zh) * | 2013-04-15 | 2013-08-14 | 陕西科技大学 | 一种基于埃博霉素b代谢途径的发酵生产方法 |
CN103667387A (zh) * | 2013-11-27 | 2014-03-26 | 陕西科技大学 | 一种从纤维堆囊菌发酵液中分离提取埃博霉素b的方法 |
CN109678938A (zh) * | 2018-12-17 | 2019-04-26 | 广东省微生物研究所(广东省微生物分析检测中心) | 一种埃博霉素生物合成基因转录调控蛋白及其制备方法 |
-
2006
- 2006-07-12 CN CN2006100910356A patent/CN101104864B/zh active Active
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101918400B (zh) * | 2008-02-01 | 2012-08-29 | 浙江海正药业股份有限公司 | 一种分离和提纯埃博霉素的方法 |
WO2009100571A1 (zh) * | 2008-02-01 | 2009-08-20 | Zhejiang Hisun Pharmaceutical Co., Ltd. | 一种分离和提纯埃博霉素的方法 |
CN102276597A (zh) * | 2010-01-12 | 2011-12-14 | 山东大学 | 14元大环内酯类埃博霉素化合物及其应用 |
CN102276597B (zh) * | 2010-01-12 | 2013-10-16 | 山东大学 | 14元大环内酯类埃博霉素化合物及其应用 |
CN102373251A (zh) * | 2011-11-04 | 2012-03-14 | 陕西科技大学 | 一种添加分子印迹聚合物的埃博霉素d发酵生产方法 |
CN102373252A (zh) * | 2011-11-04 | 2012-03-14 | 陕西科技大学 | 一种埃博霉素b的发酵生产工艺 |
CN102373252B (zh) * | 2011-11-04 | 2013-11-27 | 陕西科技大学 | 一种埃博霉素b的发酵生产工艺 |
CN102373251B (zh) * | 2011-11-04 | 2014-07-02 | 陕西科技大学 | 一种添加分子印迹聚合物的埃博霉素d发酵生产方法 |
CN103243134A (zh) * | 2013-04-15 | 2013-08-14 | 陕西科技大学 | 一种基于埃博霉素b代谢途径的发酵生产方法 |
CN103243134B (zh) * | 2013-04-15 | 2015-04-22 | 陕西科技大学 | 一种基于埃博霉素b代谢途径的发酵生产方法 |
CN103667387A (zh) * | 2013-11-27 | 2014-03-26 | 陕西科技大学 | 一种从纤维堆囊菌发酵液中分离提取埃博霉素b的方法 |
CN103667387B (zh) * | 2013-11-27 | 2015-09-30 | 陕西科技大学 | 一种从纤维堆囊菌发酵液中分离提取埃博霉素b的方法 |
CN109678938A (zh) * | 2018-12-17 | 2019-04-26 | 广东省微生物研究所(广东省微生物分析检测中心) | 一种埃博霉素生物合成基因转录调控蛋白及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101104864B (zh) | 2011-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101104864B (zh) | 埃博霉素b的制备方法 | |
CN100519757C (zh) | 台勾霉素的制备 | |
CN100590194C (zh) | 一株产纳他霉素的利迪链霉菌及其应用 | |
CN106085868A (zh) | 一株产生抗hiv活性物质的曲霉菌及其应用 | |
CN101720772B (zh) | 一种防治作物真菌病害的大环内脂类组合物及其制备工艺 | |
CN106086147A (zh) | 利用真菌激发子诱导从桦褐孔菌中提取白桦脂酸的方法 | |
CN104726347A (zh) | 一株狐粪青霉真菌菌株以及利用该菌株制备左旋7-羟基丁苯酞的方法 | |
CN101720781B (zh) | 一种防治作物真菌病害的新磷氮霉素a及其制备工艺 | |
CN103172507A (zh) | 蛇孢菌素类二倍半萜化合物及其制备方法与应用 | |
CN102293122B (zh) | 一种刺五加北虫草的培养方法 | |
CN102453015B (zh) | 一种Azaphilone类衍生物及其制备和应用 | |
CN103667387B (zh) | 一种从纤维堆囊菌发酵液中分离提取埃博霉素b的方法 | |
CN105348247B (zh) | 一种异香豆素类化合物及其制备方法和应用 | |
CN101732310B (zh) | 埃博霉素b的用途 | |
CN104164370A (zh) | 一株猴头菌及其应用 | |
CN117298250A (zh) | 一种环肽化合物在制备抗癌药物中的应用及其药物组合物 | |
CN100509963C (zh) | 竹黄菌发酵制备天然蒽醌类色素的方法 | |
CN101538247B (zh) | 一种生物碱类化合物的制备方法 | |
CN110218200A (zh) | 一种红树内生真菌中环缩肽化合物及其制备方法与应用 | |
CN103146594B (zh) | 纤维堆囊菌菌株及其在埃博霉素合成方面的应用 | |
CN102757443B (zh) | 硫取代鬼臼类衍生物及其生物转化和分离纯化方法 | |
CN105418602A (zh) | 一种海洋肽类化合物及其制备方法和应用 | |
CN101407767A (zh) | 一种通过发酵生产冬虫夏草的方法 | |
CN101280333B (zh) | 一种利用灰玫瑰青霉制备青霉源性抗菌肽的方法 | |
CN101400684A (zh) | 噻唑类化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151030 Address after: 410329 Liuyang County, Hunan biological pharmaceutical industrial park, Central Garden Road Patentee after: Hunan Dinuo Pharmaceutical Co., Ltd. Address before: 410329 Liuyang County, Hunan biological pharmaceutical industrial park, Central Garden Road Patentee before: Hunan Dinuo Pharmaceutical Co., Ltd. Patentee before: Emission and Radiation Medical Research Institute |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 410005 Kangping Road, Liuyang economic and Technological Development Zone, Changsha, Hunan, 165 Patentee after: Hunan Dino pharmaceutical Limited by Share Ltd Address before: 410329 Huan Yuan East Road, Liuyang biological medicine industrial park, Hunan Patentee before: Hunan Dinuo Pharmaceutical Co., Ltd. |